Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in:

16.09.2022 | Hepatobiliary Tumors

Association of Concurrent Metabolic Syndrome with Long-term Oncological Prognosis Following Liver Resection for Hepatocellular Carcinoma Among Patients with Chronic Hepatitis B Virus Infection: A Multicenter Study of 1753 Patients

verfasst von: Ming-Da Wang, MD, Shi-Chuan Tang, MD, Chao Li, MD, Li-Yang Sun, MD, Xiao Xu, MD, Ying-Jian Liang, MD, Fu-Bao Liu, MD, Wei-Min Gu, MD, Xian-Ming Wang, MD, Ya-Hao Zhou, MD, Wan Yee Lau, MD, FRCS, FACS, FRACS (Hon), Cheng-Wu Zhang, MD, Lan-Qing Yao, MD, Yong-Kang Diao, MD, Li-Hui Gu, MD, Feng Shen, MD, PhD, Yong-Yi Zeng, MD, Tian Yang, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Although hepatitis B virus (HBV) infection remains the main cause of hepatocellular carcinoma (HCC) worldwide, metabolic syndrome, with its increase in prevalence, has become an important and significant risk factor for HCC. This study was designed to investigate the association of concurrent metabolic syndrome with long-term prognosis following liver resection for patients with HBV-related HCC.

Methods

From a Chinese, multicenter database, HBV-infected patients who underwent curative resection for HCC between 2010 and 2020 were identified. Long-term oncological prognosis, including overall survival (OS), recurrence-free survival (RFS), and early (≤2 years of surgery) and late (>2 years) recurrences were compared between patients with versus those without concurrent metabolic syndrome.

Results

Of 1753 patients, 163 (9.3%) patients had concurrent metabolic syndrome. Compared with patients without metabolic syndrome, patients with metabolic syndrome had poorer 5-year OS (47.5% vs. 61.0%; P = 0.010) and RFS (28.3% vs. 44.2%; P = 0.003) rates and a higher 5-year overall recurrence rate (67.3% vs. 53.3%; P = 0.024). Multivariate analysis revealed that concurrent metabolic syndrome was independently associated with poorer OS (hazard ratio: 1.300; 95% confidence interval: 1.018–1.660; P = 0.036) and RFS (1.314; 1.062–1.627; P = 0.012) rates, and increased rates of late recurrence (hazard ratio: 1.470; 95% confidence interval: 1.004–2.151; P = 0.047).

Conclusions

In HBV-infected patients with HCC, concurrent metabolic syndrome was associated with poorer postoperative long-term oncologic survival outcomes. These results suggested that patients with metabolic syndrome should undergo enhanced surveillance for tumor recurrence even after 2 years of surgery to early detect late HCC recurrence. Whether improving metabolic syndrome can reduce postoperative recurrence of HCC deserves further exploration.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.CrossRef
2.
Wong M, Huang J, George J, Huang J, Leung C, Eslam M, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol. 2019;16:57–73.CrossRef
3.
Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3:1683–91.CrossRef
4.
Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-medicare database. Hepatology. 2011;54:463–71.CrossRef
5.
Li R, Li W, Lun Z, Zhang H, Sun Z, Kanu JS, et al. Prevalence of metabolic syndrome in Mainland China: a meta-analysis of published studies. BMC Public Health. 2016;16:296.CrossRef
6.
Yang M, Wei L. Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia. Liver Int. 2022.
7.
Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, et al. A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg. 2016;263:1112–25.CrossRef
8.
Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–80.CrossRef
9.
Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–7.CrossRef
10.
Wang MD, Li C, Liang L, Xing H, Sun LY, Quan B, et al. Early and Late Recurrence of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Oncologist. 2020;25:e1541-1541e1551.CrossRef
11.
Xu XF, Xing H, Han J, Li ZL, Lau WY, Zhou YH, et al. risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg. 2019;154:209–17.CrossRef
12.
Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51:890–7.CrossRef
13.
Sohn W, Paik YH, Kim JM, Kwon CH, Joh JW, Cho JY, et al. HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma. Ann Surg Oncol. 2014;21:2429–35.CrossRef
14.
Du ZG, Wei YG, Chen KF, Li B. Risk factors associated with early and late recurrence after curative resection of hepatocellular carcinoma: a single institution’s experience with 398 consecutive patients. Hepatobiliary Pancreat Dis Int. 2014;13:153–61.CrossRef
15.
Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411–28.CrossRef
16.
Borena W, Strohmaier S, Lukanova A, Bjørge T, Lindkvist B, Hallmans G, et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer. 2012;131:193–200.CrossRef
17.
Jinjuvadia R, Patel S, Liangpunsakul S. The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. J Clin Gastroenterol. 2014;48:172–7.CrossRef
18.
Pawlik TM, Soubrane O. Metabolic syndrome-associated hepatocellular carcinoma: questions still unanswered. J Hepatol. 2015;63:8–9.CrossRef
19.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.CrossRef
20.
Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2010;375:181–3.CrossRef
21.
[Expert recommendations on standardized diagnosis and treatment for fatty liver disease in China (2019 revised edition)]. Zhonghua Gan Zang Bing Za Zhi. 2019;27:748–53.
22.
Yu JJ, Shen F, Chen TH, Liang L, Han J, Xing H, et al. Multicentre study of the prognostic impact of preoperative bodyweight on long-term prognosis of hepatocellular carcinoma. Br J Surg. 2019;106:276–85.CrossRef
23.
Strasberg SM, Phillips C. Use and dissemination of the brisbane 2000 nomenclature of liver anatomy and resections. Ann Surg. 2013;257:377–82.CrossRef
24.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRef
25.
Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229–35.CrossRef
26.
Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet. 2005;365:1398–405.CrossRef
27.
Xing Y, Xu S, Jia A, Cai J, Zhao M, Guo J, et al. Recommendations for revision of Chinese diagnostic criteria for metabolic syndrome: a nationwide study. J Diabetes. 2018;10:232–9.CrossRef
28.
Ma WY, Yang CY, Shih SR, Hsieh HJ, Hung CS, Chiu FC, et al. Measurement of Waist Circumference: midabdominal or iliac crest. Diabetes Care. 2013;36:1660–6.CrossRef
29.
Yoshida N, Takayama T, Midorikawa Y, Higaki T, Nakayama H, Moriguchi M, et al. Surgical outcomes in patients with hepatocellular carcinoma associated with metabolic syndrome. World J Surg. 2015;39:471–7.CrossRef
30.
Cauchy F, Zalinski S, Dokmak S, Fuks D, Farges O, Castera L, et al. Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome. Br J Surg. 2013;100:113–21.CrossRef
31.
Viganò L, Conci S, Cescon M, Fava C, Capelli PD et al. Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: a multicenter matched analysis with HCV-related HCC. J Hepatol. 2015;63:93–101.
32.
Tian Y, Lyu H, He Y, Xia Y, Li J, Shen F. Comparison of hepatectomy for patients with metabolic syndrome-related HCC and HBV-related HCC. J Gastrointest Surg. 2018;22:615–23.CrossRef
33.
Jia HD, Liang L, Li C, Wu H, Wang H, Liang YJ, et al. Long-term surgical outcomes of liver resection for hepatocellular carcinoma in patients with HBV and HCV co-infection: a multicenter observational study. Front Oncol. 2021;11:700228.CrossRef
34.
Wu Y, Dong Y, Duan S, Zhu D, Deng L. Metabolic syndrome, inflammation, and cancer. Mediators Inflamm. 2017;2017:8259356.
35.
Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135:111–21.CrossRef
Metadaten
Titel
Association of Concurrent Metabolic Syndrome with Long-term Oncological Prognosis Following Liver Resection for Hepatocellular Carcinoma Among Patients with Chronic Hepatitis B Virus Infection: A Multicenter Study of 1753 Patients
verfasst von
Ming-Da Wang, MD
Shi-Chuan Tang, MD
Chao Li, MD
Li-Yang Sun, MD
Xiao Xu, MD
Ying-Jian Liang, MD
Fu-Bao Liu, MD
Wei-Min Gu, MD
Xian-Ming Wang, MD
Ya-Hao Zhou, MD
Wan Yee Lau, MD, FRCS, FACS, FRACS (Hon)
Cheng-Wu Zhang, MD
Lan-Qing Yao, MD
Yong-Kang Diao, MD
Li-Hui Gu, MD
Feng Shen, MD, PhD
Yong-Yi Zeng, MD
Tian Yang, MD
Publikationsdatum
16.09.2022
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2023
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12529-6

Weitere Artikel der Ausgabe 1/2023

Just a Little Bit of Anaplastic Thyroid Cancer?

  • Endocrine Tumors

CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma

  • Open Access
  • Pancreatic Tumors

ASO Author Reflections: Management of Recurrent Pseudomyxoma Peritonei After Cytoreductive Surgery and HIPEC

  • ASO Author Reflections

Understanding Racial Differences in Lung Cancer Surgery Through a Statewide Quality Collaborative

  • Thoracic Oncology

Disparities in Care Access to Liver-Directed Therapy Among Medicare Beneficiaries with Colorectal Cancer Liver Metastasis

  • Hepatobiliary Tumors

Evaluating Axillary Lymph Node Yield After Neoadjuvant Chemotherapy

  • Breast Oncology

Neu im Fachgebiet Chirurgie

Nach Vollremission bei Ösophagus-Ca. – Operation erstmal aussetzen?

Studienziel erreicht, dennoch viele Fragen offen. So lassen sich die Ergebnisse der SANO-Studie zur Active-Surveillance versus sofortigen Ösophagektomie nach neoadjuvanter Komplettremission zusammenfassen. Interessant sind die Daten so oder so.

Nicht weniger Infektionen unter Vakuumversiegelungstherapie

Nach Ergebnissen der britisch-australischen SUNRISE-Studie scheint eine Unterdruck-Wundtherapie Infektionen bei abdominell Notoperierten nicht besser verhindern zu können als eine herkömmliche Wundversorgung.

Vergessene OP-Unterlage erst zwei Monate postoperativ entdeckt

Es sollte nie passieren, passiert aber doch: chirurgisches Material, das unbemerkt im Körper verbleibt. Im vorliegenden Fall wurde der Fremdkörper trotz seiner Größe erst nach zwei Monaten entdeckt – nachdem der Patient fast daran gestorben wäre.

Nur selten ernste Komplikationen bei endoskopischer Sinuschirurgie

Etwa 3% der Menschen mit einer endoskopischen Nasennebenhöhlenoperation entwickeln ausgeprägtes Nasenbluten. Andere Komplikationen, wie Verletzungen des Nervus opticus oder eine Meningitis, treten nur äußerst selten auf, legt eine Registeranalyse nahe.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise